Skip to content

Addiction: all studies

Page 396 of 857: studies 3,951 to 3,960 of 8,563, newest first. Back to the addiction overview

Research

Applying Key Lessons from the Hospice and Palliative Care Movement to Inform Psychedelic-Assisted Therapy.

Psychedelic Medicine September 1, 2023 Megan Miller, William E Rosa, Alden Doerner Rinaldi et al. 9 citations

Psychedelic-assisted therapy (PAT) has re-emerged as a promising intervention for addressing mental health conditions and existential concerns. Despite growing enthusiasm, PAT may be difficult to integrate into mainstream health systems. The rich sacramental traditions of psychedelics, their centering of the human experience, proposed substrates of action, context-dependent outcomes, and highly...

Neuroimaging in psychedelic drug development: past, present, and future.

Molecular Psychiatry September 1, 2023 Matthew B. Wall, Rebecca Harding, Rayyan Zafar et al. 39 citations

Psychedelic therapy (PT) is an emerging paradigm with great transdiagnostic potential for treating psychiatric disorders, including depression, addiction, post-traumatic stress disorder, and potentially others. 'Classic' serotonergic psychedelics, such as psilocybin and lysergic acid diethylamide (LSD), which have a key locus of action at the 5-HT2A receptor, form the main focus of this...

DOI: 10.1038/s41380-023-02271-0 (opens in new tab) Full text (opens in new tab) Psychedelics Mental health Brain imaging Pharmacology

Predictors of Pharmacy Students' Attitudes About the Therapeutic Use of Psilocybin.

Cureus September 1, 2023 Nm Mahmudul Alam Bhuiya, Robin J Jacobs, Karina Wang et al. 3 citations

Background Psilocybin has been studied for its potential therapeutic benefits, particularly for the treatment of psychiatric disorders such as anxiety, depression, and obsessive-compulsive disorder. While more research is needed as psilocybin-assisted therapy becomes more prevalent, future pharmacists will probably be involved at some level. At present, pharmacists receive minimal training on...

Hallucinogen-Induced Persisting Perception Disorder: A Case Report.

Cureus September 1, 2023 Javairia Ayyub, Sailaja Nandennagari, Dylan Edelbaum et al. 1 citation

Hallucinogen-persisting perception disorder (HPPD), also known as acute hallucinogen-induced psychosis or informally known as "flashbacks," is an unusual condition experienced by patients due to the use of different hallucinogenic substances. Hallucinogen-persisting perception disorder causes many symptoms, predominantly persistent visual perception distortion instead of intermittent...

DOI: 10.7759/cureus.46262 (opens in new tab) Full text (opens in new tab) Lysergic acid diethylamide Alpha-2 adrenergic agonists Antiepileptic medications Benzodiazepines +4

The View of Death and the Funeral Protocols of Orok in the Far East

Institute for Russian and Altaic Studies Chungbuk University August 31, 2023 Soon Cheon Eom

This paper examines the death view and customs of the orok, which belong to the three major indigenous peoples of Sakhalin Island along with the paleoasiatic nivh and tungusic evenki. The orok link life and death with the presence or absence of a soul. Life is a state in which the soul resides in the body, and death is a state in which the soul is separated from the body. The funeral protocols...

Psilocybin history, action and reaction: A narrative clinical review

Journal of Psychopharmacology August 31, 2023 Pravesh Sharma, Quang Anh Nguyen, Erin Carpenter et al. 32 citations

Hallucinogenic mushrooms have been used in religious and cultural ceremonies for centuries. Of late, psilocybin, the psychoactive compound in hallucinogenic mushrooms, has received increased public interest as a novel drug for treating mood and substance use disorders (SUDs). In addition, in recent years, some states in the United States have legalized psilocybin for medical and recreational...

Single-Dose Psilocybin Treatment for Major Depressive Disorder

JAMA August 31, 2023 Charles L. Raison, Gerard Sanacora, Joshua Woolley et al. 493 citations

Importance Psilocybin shows promise as a treatment for major depressive disorder (MDD). Objective To evaluate the magnitude, timing, and durability of antidepressant effects and safety of a single dose of psilocybin in patients with MDD. Design, Setting, and Participants In this phase 2 trial conducted between December 2019 and June 2022 at 11 research sites in the US, participants were...

DOI: 10.1001/jama.2023.14530 (opens in new tab) Full text (opens in new tab) Psilocybin therapy Clinical depression treatment Psychedelic medicine Mental health research +1

Ligand-Free Signaling of G-Protein-Coupled Receptors: Physiology, Pharmacology, and Genetics.

Molecules August 31, 2023 Wolfgang Sadee 8 citations

G-protein-coupled receptors (GPCRs) are ubiquitous sensors and regulators of cellular functions. Each GPCR exists in complex aggregates with multiple resting and active conformations. Designed to detect weak stimuli, GPCRs can also activate spontaneously, resulting in basal ligand-free signaling. Agonists trigger a cascade of events leading to an activated agonist-receptor G-protein complex...

The changing outlook of psychedelic drugs: The importance of risk assessment and occupational exposure limits

Journal of Applied Toxicology August 30, 2023 Natália Bernardi Videira, Vijayalekshmi Nair, Valérie Paquet et al. 2 citations

Abstract Serotonergic psychedelics, such as lysergic acid diethylamide (LSD), psilocybin, dimethyltryptamine (DMT), and 5‐methoxy‐ N , N ‐dimethyltryptamine (5‐MeO‐DMT), are currently being investigated for the treatment of psychiatric disorders such as depression and anxiety. Clinical trials with psilocybin and LSD have shown improvement in emotional and psychological scores. Although these...

Double-Blind Comparison of the Two Hallucinogens Dextromethorphan and Psilocybin: Experience-Dependent and Enduring Psychological Effects in Healthy Volunteers

Psychedelic Medicine August 30, 2023 Samantha Hilbert, David S. Mathai, Nathan D. Sepeda et al. 10 citations

This analysis suggests the utility of exploring clinical applications of dissociatives that occur within the supportive contexts that are characteristic of psychedelic research and that prioritize the optimization of psychologically valuable drug experiences. This study was registered with ClinicalTrials.gov (NCT02033707).